Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTS78AZ)

• DTT Name: Prostate specific antigen (KLK3) DTT Info
• Gene Name: KLK3

Molecule-Related Drug & Molecule List

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Motexafin lutetium	DM8K5Z6	Artery stenosis	BD52	Phase 3	[1]
ProstaVac	DM5FZH4	Prostate hyperplasia	GA90	Phase 3	[2]
PRX-302	DMEH641	Prostate cancer	2C82.0	Phase 3	[3]
Rilimogene galvacirepvec	DMGTCI0	Prostate cancer	2C82.0	Phase 3	[4]
ADXS-PSA	DMOPVET	Prostate cancer	2C82.0	Phase 1/2	[2]
MVA-BN Breast	DMFMW5C	Prostate cancer	2C82.0	Phase 1	[5]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-PSA mabs	DMO21T7	Prostate cancer	2C82.0	Investigative	[2]
PMID23692593C20	DM1T9LJ	Discovery agent	N.A.	Investigative	[6]
ProstaRex	DM9GFOM	Prostate cancer	2C82.0	Investigative	[2]
VTT-201	DMT967L	Prostate cancer	2C82.0	Investigative	[2]

References

• [1] Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
• [3] Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54.
• [4] Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105.
• [5] Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44.
• [6] Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35.